Vivoryon Therapeutics to Attend 38th Annual J.P. Morgan Healthcare Conference in January 2020
Vivoryon Therapeutics to Attend Upcoming Investor Conferences
HALLE (SAALE), Germany and Herlev, Denmark, 14 January 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) and Nordic Bioscience, announced today an agreement to collaborate for the clinical development of PQ912 for Alzheimer’s Disease (AD). In addition to taking on the role as CRO (Clinical Research Organization) for Vivoryon Therapeutics’ Phase 2b SAPHIR 2 trial, Nordic Bioscience and Vivoryon will enter into a collaboration to benefit from Nordic Bioscience’s world leading expertise in the development of blood-based biomarkers for the identification of specific patients that may benefit most from treatment with PQ912, the Company’s Phase 2 clinical-stage candidate in AD.
Current methods used to diagnose AD remain invasive and relatively complex. Therefore, there is a need to develop and establish reliable, less invasive and efficient biomarkers and technologies in clinical practice. To address this, Nordic Bioscience has been pioneering the development of blood‑based biomarkers for decades and is therefore the ideal partner for identifying molecular fingerprints in blood of patients. This supports Vivoryon’s therapeutic approach of targeting neurotoxic pGlu‑Abeta by inhibiting its producing enzyme Glutaminyl Cyclase.
For the biomarker activities, blood samples of patients in the European SAPHIR 2 Phase 2b trial will be collected and analyzed by a mutual team of scientists from Nordic Bioscience and Vivoryon Therapeutics with the goal to identify correlations with clinical responses.
“We believe our collaboration with Nordic Bioscience has the potential to bring tremendous benefit to patients suffering from this complex and devastating disease. The ability to select patients who have a greater chance of responding to PQ912 could transfer an already proven principle of precision medicine into Alzheimer’s Disease. We look forward to the start of our Phase 2b clinical trial in the first quarter of 2020.” commented Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics AG.
“Vivoryon’s approach to treating Alzheimer’s disease provides multiple options to identify predictive response markers in blood. As such, we are excited about the potential of this partnership.” said Claus Christiansen, Chairman of Nordic Bioscience.
###
For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Email: contact@vivoryon.com
Nordic Bioscience
Thomas Nielsen, CFO
Email: tn@nordicbio.com
Trophic Communications
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 172 861 8540 / +49 176 2103 7191
Email: Trophic@vivoryon.com
About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer’s disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications.
About Nordic Bioscience
Nordic Bioscience is dedicated to preclinical and clinical drug development, and specialized in precision medicine using unique biomarker technologies. Nordic Bioscience engage with biotech and pharmaceutical clients to identify projects most suitable for clinical development by utilizing a proprietary biomarker technology.
Nordic Bioscience has more than 25 years’ experience in biomarker development and clinical trials and has particularly acquired extensive expertise in rheumatology. Combining experience in preclinical and clinical research enables a faster and smarter detection of signals of the potential clinical viability of drug candidates.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.